On February 25, 2021 Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) reported that they have entered into a strategic research alliance (Press release, Harvard University, FEB 25, 2021, View Source [SID1234575687]). The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kyowa Kirin is a Japan-based global specialty pharmaceutical company with drug discovery and commercialization capabilities focused in core therapeutic areas of nephrology, oncology, immunology and allergy, and the central nervous system. By creating opportunities for formal scientific collaboration, the alliance will leverage industry insight and drug development expertise to advance biomedical innovations developed in Harvard labs toward the clinical development of important new therapies.

"Fundamental research conducted in Harvard’s life-science labs expands our basic understanding of the biological mechanisms of disease and identifies promising new approaches to treatment," said Vivian Berlin, Managing Director of Strategic Partnerships in Harvard OTD. "By building collaborative scientific relationships around the world, like this alliance with Kyowa Kirin, we are crafting an environment where industry leadership, resources, and new scientific perspectives may help to validate and develop those innovations toward life-changing treatments for the benefit of patients."

"I am very pleased that Kyowa Kirin will have the opportunity to work and collaborate with the faculty at one of the world’s leading institutions to advance drug discovery and biomedical science," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin. "One of our most important R&D strategies is to pursue external opportunities to generate scientific innovative value through strategic collaborations with industry and academia. I’m confident that this alliance will lead us toward novel and promising therapies for patients in the future."

Projects under the alliance will be initiated by Harvard’s leading life-science faculty through a proposal process. Projects selected for funding and scientific collaboration will be identified by a Joint Steering Committee, comprising membership from both Harvard and Kyowa Kirin.

Harvard OTD’s long-running alliance program creates multi-year, collaborative relationships between the University and corporate partners. These alliances support faculty-initiated research projects that can advance early-stage discoveries and rapidly drive innovation in a broad area of science. In establishing discussions with Kyowa Kirin that led to the creation of this research alliance, OTD was assisted by Gemseki, Inc., a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), a preclinical CRO in Japan.